Anjali Sibley MD, MPH
Clinical Associate Professor, Medicine - Oncology
Bio
Dr. Sibley is a Clinical Associate Professor of Medicine (Oncology) at Stanford School of Medicine. She is the Director of the Stanford Medicine Cancer Center in Emeryville and is a board-certified, fellowship-trained hematologist and medical oncologist.
Her clinical interests include treating solid tumor cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in hematologic/oncologic care among underserved populations, and successful cancer survivorship programs.
In addition to responsibilities related to patient care and overseeing the Cancer Center in Emeryville, Dr. Sibley has developed and is leading an innovative cancer survivorship clinic, including an exercise initiative. She also is passionate about advancing clinical trial enrollment for medically underserved populations and she serves on the Cancer Network’s East Bay Health Equity Committee leading lung cancer screening efforts in the East Bay. She is also working on a Stanford Cancer Institute-funded study examining psychosocial factors and cardiac health in Black cancer patients in the East Bay.
She believes that providing patient care is a true privilege. Dr. Sibley utilizes a patient-centered practice approach that addresses multiple aspects of a patient’s well-being. Her research interests have included chemoprevention of breast cancer and the development of magnetic resonance imaging technology in breast cancer detection and mapping. She has also led community-based efforts to implement low-dose computed tomography (LDCT) as a screening tool for cancer.
Dr. Sibley’s publications include articles on breast cancer prevention, breast magnetic resonance imaging, and other topics. Her work has appeared in American Journal of Hematology, JAMA, the Breast Journal, Internal Medicine News, and elsewhere. Dr. Sibley was invited to deliver a peer-reviewed presentation on community-based cancer screening and preventive education to the Global Health Council. Dr. Sibley is on the board of directors of the Cancer Support Community SF Bay Area. She has also served as a clinic physician for the Native American Health Center of Oakland, on the Committee on Health Equity of the American Public Health Association, and as chair and vice chair of the Cancer Forum Caucus of the American Public Health Association. She is a member of the American Society of Clinical Oncology, American Society of Preventive Oncology, and American Society of Hematology. She has provided volunteer services to the Global Health Council and to the Cancer Patients Aid Association, for whom she conducted a patient screening and education program in Mumbai, India.
Clinical Focus
- Medical Oncology
Professional Education
-
Board Certification: American Board of Internal Medicine, Medical Oncology (2023)
-
Board Certification: American Board of Internal Medicine, Hematology (2023)
-
Fellowship: University of Arkansas Hematology and Medical Oncology Fellowship (2010) AR
-
Residency, Internal Medicine, Harvard Medical School/Mount Auburn Hospital, MA (2007)
-
Medical Education: University of Tennessee College of Medicine (2003) TN
All Publications
-
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.
Cancer
2025; 131 (17): e70060
Abstract
Clinical practice guidelines for nonsmall cell lung cancer (NSCLC) and small cell lung cancer include recommendations based on high-level clinical trial evidence, but complex clinical questions are frequently seen in real-world practice that are not clearly answered by prospective trial data. To address these questions, the Bridging the Gaps Lung Cancer Consensus Conference 2024 (BtG LCCC 2024) convened to develop US-focused expert guidance for clinical situations in which level 1 evidence is lacking. At BtG LCCC 2024, a multidisciplinary expert panel discussed ongoing clinical issues in small cell lung cancer management, targeted therapy in EGFR-mutated NSCLC, management of early stage NSCLC, identification and management of non-EGFR oncogene-driven NSCLC, and use of immunotherapy in advanced/metastatic NSCLC. By using a modified Delphi process, 12 consensus recommendations were developed with the goal of providing guidance on the use of novel diagnostic methods and treatments for clinicians who manage lung cancer. This report reviews these areas of consensus and discusses ongoing questions about ways to apply current clinical evidence.
View details for DOI 10.1002/cncr.70060
View details for PubMedID 40856114
-
QIM25-226: What Patients Anticipate About Working Out with Cancer: Qualitative Survey Results.
Journal of the National Comprehensive Cancer Network : JNCCN
2025; 23 (3.5)
View details for DOI 10.6004/jnccn.2024.7282
View details for PubMedID 40154399
-
Using Patient-Related Outcomes Data to Inform About a Novel Exercise Program in Oncology Patients.
Journal of cancer education : the official journal of the American Association for Cancer Education
2024
View details for DOI 10.1007/s13187-024-02470-5
View details for PubMedID 38954163